Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Observational Registry Study With Sub-analysis (Patients Previously Randomized to LAMBDA 001) to Assess ProsperaTM Performance for Detection of CLAD After Lung Transplant (LAMBDA 002)

NCT05170425 is registered in ClinicalTrials.gov with Natera, Inc. as lead sponsor.

NCT NCT05170425
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05170425 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Observational Registry Study With Sub-analysis (Patients Previously Randomized to LAMBDA 001) to Assess ProsperaTM Performance for Detection of CLAD After Lung Transplant (LAMBDA 002)
Lead sponsor
Natera, Inc.
Phase
Observational
Overall status
Active, not recruiting
Start date
November 4, 2022
Completion date
May 31, 2027
Enrollment
154 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

lung transplant rejection